Tumor microenvironment: The role of the tumor stroma in cancer

Journal of Cellular Biochemistry

Volumn 101, Issue 4, 2007, Pages 805-815

  Li, Hanchen ^a   Fan, Xueli ^a   Houghton, JeanMarie ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Bone marrow derived stem cells; Cancer associated fibroblasts; Mesenchymal stem cells; Neovascularization; Tumor microenvironment; Tumor stroma; Tumor associated inflammation

Indexed keywords

CANCER GROWTH; CANCER LOCALIZATION; CELL GROWTH; GROWTH REGULATION; HEMATOPOIETIC STEM CELL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MICROENVIRONMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW; STROMA;

ANIMALS; BONE MARROW CELLS; EPITHELIAL CELLS; HUMANS; MESENCHYMAL STEM CELLS; MODELS, BIOLOGICAL; NEOPLASMS; STROMAL CELLS;

EID: 34447276000     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21159     Document Type: Review

References (61)

1. Aractingi SJ, Kanitakis S, Euvrard C, Le Danff I, Peguillet K, Khosrotehrani K, Latz O, Carosella ED. 2005. Skin carcinoma arising from donor cells in a kidney transplant recipient. Cancer Res 65:1755-1760.
2. Barilla ML, Crsons SE. 2000. Fibronectin fragments and their role in inflammatory arthritis. Semin Arthritis Rheum 29:252-265.
3. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU. 2003. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348(10):891-899.
4. Berger JA, Kipps TJ. 2006. CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107:1761-1767.
5. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL. 2004. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303: 848-851.
6. Bindra RS, Glazer PM. 2005. Genetic instability and the tumor microenvironment: Towards the concept of microenvironment-induced mutagenesis. Mutat Res 569:75-85.
7. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos S. 2005. Par1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120:303-313.
8. Carmeliet P. 2005. VEGF as a key mediator of angiogenesis in cancer. Oncology 69:4-10.
9. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK. 2000. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82:1364-1369.
10. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME. 2004. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10:858-864.
11. Clayton A, Evans RA, Pettit E, Hallett M, Williams JD, Steadman R. 1998. Cellular activation through the ligation of intercellular adhesion molecule-1. J Cell Sci 111:443-453.
12. Comerford KM, Wallace TJ, Karhausen J, Louid NA, Montalto MC, Colgan SP. 2002. Hypoxia inducible factor-1 dependent regulation of the mutlidrug resistance (MDR1) gene. Cancer Res 62:3387-3394.
13. Coussens LM, Tinkle CL, Hanahan D, Werb Z. 2000. MMP-9 supplied by bone marrow derived cells contributes to skin carcinogenesis. Cell 103:481-490.
14. Coussens LM, Fingleton B, Matrisian LM. 2002. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295:2387-2392.
15. Crivellato F, Ribatti D. 2005. Involvement of mast cells in angiogenesis and chronic inflammation. Curr Drug Targets Inflamm Allergy 4:9-11.
16. Direkze NC, Hodivala-Dilke K, Jeffery R, Hunt T, Poulsom R, Oukrif D, Alison MR, Wright NA. 2004. Bone marrow contribution to tumor associated myofibroblasts and fibroblasts. Cancer Res 64:8492-8495.
17. Dvorak HF. 2005. Angiogenesis: Update. J Thromb Haemost 3:1835-1842.
18. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. 1999. Reciprocal positive regulation of hypoxia inducible factor 1 alpha and insulin like growth factor 2. Cancer Res 59:3915-3918.
19. Genis L, Galvez BG, Gonzalo P, Arroyo AG. 2006. MT1-MMP: Universal or particular player in angiogenesis? Cancer Metastasis Rev 25:77-86.
20. Guo LJ, Luo XH, Xie H, Zhou HD, Yuan LQ, Wang M, Liao EY. 2006. Tissue inhibitor of matrix metalloproteinase-1 suppresses apoptosis of mouse bone marrow stromal cell line MBA-1. Calcif Tissue Int 78:285-292.
21. Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, Hicklin DJ, Zhu Z, Witte L, Crystal RG, Moore MA, Rafii S. 2001. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 193:1005-1014.
22. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Goldenring J, Fox JG, Wang TC. 2004. Gastric cancer originating from bone marrow-derived cells. Science 306:1568-1571.
23. Houghton AM, Grisolano JL, Baumann ML, Kobayashi DK, Hautamaki RD, Nehring LC, Cornelius LA, Shapiro SD. 2006. Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res 66:6149-6155.
24. Iwaguro H, Yamaguchi J, Kalka C, Murasawa S, Masuda H, Hayashi S, Silver M, Li T, Isner JM, Asahara T. 2002. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 105:732-738.
25. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilsonet EG. 2002. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110:341-350.
26. Jodele S, Chantrain CF, Blavier L, Lutzko C, Crooks GM, Shimada H, Coussens LM, Declerck YA. 2005. The contribution of bone marrow derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res 65:3200-3208.
27. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, l Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D. 2005. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820-827.
28. Kopelovich L. 1982. Genetic predisposition to cancer in man: In vitro studies. Int Rev Cytol 77:63-88.
29. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, Richardson A, Weinberg RA. 2004. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA 101:4966-4971.
30. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Enget C. 2002. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 32:355-357.
31. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shaffie S. 1980. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284:67-68.
32. Nishi H, Nakada T, Kyo S, Inoue M, Shay JW, Isaka K. 2004. Hypoxia inducible factor 1 mediates upregulation of telomerase (hTERT). Mol Cell Biol 24:6076-6083.
33. Okuyama H, Krishnamachary B, Zhou YF, Nagasawa H, Bosch-Marce M, Semenza GL. 2006. Expression of vascular endothelial growth factor receptor 1 in bone marrow derived mesenchymal cells is dependent on hypoxia inducible factor 1. J Biol Chem 281:15554-15563.
34. Overall CM, Dean RA. 2006. Degradomics: Systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev 25:69-75.
35. Pei D. 2005. Matrix metalloproteinases target protease-activated receptors on the tumor cell surface. Cancer Cells 7:207-208.
36. Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC. 2005. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 11:261-262.
37. Petersen OW, Nielsen HL, Gudjonsson T, Villadsen R, Rank F, Niebuhr E, Bissell MJ, Rønnov-Jessen L. 2003. Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol 162:391-402.
38. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. 1997. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599.
39. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, Werb Z, Bissell MJ. 2005. Rac1b and reactive oxygen species mediate MMP3-induced EMT and genomic instability. Nature 436:123-127.
40. Ribatti D, Vacca A, Nico B, Ria R, Dammacco F. 2002. Cross talk between hematopoiesis and angiogenesis signaling pathways. Curr Mol Med 2:537-547.
41. Ribatti D, Vacca A, Dammacco F. 2003. New non-angiogenesis dependent pathways for tumor growth. Eur J Cancer 39:1835-1841.
42. Ronnov-Jessen L, Petersen OW. 1993. Induction of α-smooth muscle actin by transforming growth factor-β1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest 68:696-707.
43. Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, Bernad A. 2005. Spontaneous human adult stem cell transformation. Cancer Res 65:3035-3039.
44. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. 2003. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883-890.
45. Sangeletti S, Stoppacciaro A, Guiducci C, Torrisi MR, Colombo MP. 2003. Leukocyte rather than tumor-produced SPARC determines stroma and collagen type IV deposition in mammary carcinoma. J Exp Med 198: 1475-1485.
46. Schor SL. 1986. Occurrence of a fetal fibroblast phenotype in familial breast cancer. Int J Cancer 37:831-836.
47. Schreinemachers DM, Everson RB. 1994. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138-146.
48. Serafini P, De Santo C, Marigo I. 2004. Derangement of immune responses by meyloid suppressor cells. Cancer Immunol Immunother 53:64-72.
49. Serakinci NP, Guldberg JS, Burns B, Abdallah H, Schrodder H, Jensen T, Kassem M. 2004. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 23:5095-5098.
50. Siegel PM, Massague J. 2003. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nature 3: 807-820.
51. Silzle T, Randolph GJ. 2004. The fibroblast: Sentinel cell and local immune modulator in tumor tissue. Int J Cancer 108:173-180.
52. Sternlicht MD, Werb Z. 2001. How matric metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463-516.
53. Stringer SE. 2006. The role of heparan sulphate proteoglycans in angiogenesis. Biochem Soc Trans 34:451-453.
54. Stuelten CH, DaCosta Byfield S, Arany PR, Karpova TS, Stetlerr-Stevenson WG, Roberts AB, Anita B. 2005. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci 118:2143-2153.
55. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T. 1999. Ischemia and cytokine induced mobilization of bone marrow derived endothelial progenitor cell for neovascularization. Nat Med 5:434-438.
56. Takura N. 2006. Role of hematopoietic lineage cells as accessory components in blood vessel formation. Cancer Sci 97:568-574.
57. Thun MJ, Henley SJ, Patrono C. 2002. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252-266.
58. Tuhkanen H. 2004. Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p. Int J Cancer 109:247-252.
59. Yamaguchi J, Kusano KF, Masou O, Kawamoto A, Silver M, Murasawa S, Bosch-Marce M, Masuda H, Losordo DW, Isner JM, Asahara T. 2003. Stromal cell-derived factor 1 effects an ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 107:1316-1322.
60. Yang L, DeBusk LM, Fukuda K. 2004. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409-421.
61. Zeisberg M, Strultz F, Muller GA. 2000. Role of fibroblast activation in inducing interstitial fibrosis. J Nephrol 13: S111-S120.